You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

  Sign up to receive our twice-weekly e-Newsletter
 HIV and Hepatitis.com Coverage of the
49
th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009)
September 12-15, 2009, San Francisco, CA
 The material posted on HIV and Hepatitis.com about the 49th ICAAC is not approved by the American Society for Microbiology

Library of Slides and Posters
HIV and AIDS Articles
Hepatitis B or C Articles
HIV-HCV or HIV-HBV Coinfection Articles

Assessing Best Practices
in HIV/AIDS Therapy -
Independent Coverage
of ICAAC 2009



Library of Slides and Posters
Steady State Evaluation of Two Extended Release (XR) Nevirapine (NVP) Tablets 400 mg QD Compared with Immediate Release (IR) NVP Tablets 200 mg BID in HIV-1 Infected Patients
A. Quinson
and others. ICAAC 2009.
Early Virological and Immunological Response is Comparable between Nevirapine and RTV-boosted Atazanavir: An ARTEN Sub-analysis
J Soriano
and others. ICAAC 2009.
Pharmacokinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers
M Schöller-Gyüre
and others. ICAAC 2009.
GRACE (Gender, Race And Clinical Experience): Etravirine (ETR) Subgroup Analysis at Week 48
S Hodder and others. ICAAC 2009.
GRACE (Gender, Race And Clinical Experience): Outcomes by Race at Week 48
K Smith and others. ICAAC 2009.
Bioavailability and food effect of darunavir following administration of an oral suspension
V Sekar and others. ICAAC 2009.
Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir and buprenorphine/naloxone
V Sekar and others. ICAAC 2009.
Insertions at positions 33 and 35 of the HIV-1 protease: prevalence and role in virologic failure in darunavir-treated patients
S De Meyer and others. ICAAC 2009.
Pharmacokinetic interaction between etravirine and lopinavir/ritonavir
M Schöller-Gyüre and others. ICAAC 2009.
Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer GS-9350 versus Ritonavir
S Ramanathan and others. ICAAC 2009.
Effect of Food on Pharmacokinetics of Elvitegravir, Emtricitabine, Tenofovir DF and the Pharmacoenhancer GS-9350 as a Fixed- Dose Combination Tablet
P German and others. ICAAC 2009.
HIV Testing Among Patients Screened, Diagnosed, or Treated for Sexually Transmitted Diseases
J Chen and others. ICAAC 2009.
Improvement in Fasting Lipids but Minimal Recovery of Limb Fat Were Seen 96 Weeks After Switching from Lamivudine/Zidovudine Plus Efavirenz to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-Infected Patients
E DeJesus and others. ICAAC 2009.
Lack of a Clinically Important Effect of Rifabutin (RFB) on Raltegravir (RAL) Pharmacokinetics
D Brainard and others. ICAAC 2009.
Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 48-Week Data
E DeJesus and others. ICAAC 2009.
HIV Integrase Inhibitors Do Not Exert A Post-Antibiotic Effect Despite Slow Dissociation From IN-DNA Complexes In Vitro
R Hluhanich and others. ICAAC 2009.
Raltegravir Demonstrates Durable Efficacy Through 96 Weeks: Results from STARTMRK, A Phase III Study of Raltegravir-based vs. Efavirenz-based Therapy in Treatment-Naïve HIV+ Patients
J Lennox and others. ICAAC 2009.
TDF-containing Antiretroviral Regimens in Pregnancy: Findings from the Antiretroviral Pregnancy Registry
K Squires and others. ICAAC 2009.
Vicriviroc Long-term Safety and Efficacy: 96-Week Results from the VICTOR-E1 Study
M McCarthy and others. ICAAC 2009.
Clonal Analysis of the gp120 V3 Loop from Clinical Isolates Displaying Phenotypic Resistance to Vicriviroc
P McNicholas and others. ICAAC 2009.
Assessment of Pharmacokinetic and Safety Interactions Between Vicriviroc and CYP3A4 Substrates, Inhibitors, and Inducers
C Kasserra and others. ICAAC 2009.
Discovery of GS-9350: A Novel Pharmacoenhancer without Anti-HIV Activity
L Xu and others. ICAAC 2009.

HIV and AIDS Articles
HIV Maturation Inhibitor Bevirimat Demonstrates Promising Safety and Efficacy in Patients with Responsive HIV Genotype
Investigational Pharmaco-enhancer GS-9350 Equals Ritonavir (Norvir) as a Booster for Atazanavir (Reyataz)
Raltegravir (Isentress) Demonstrates Safety and Antiviral Efficacy at 24 Weeks in Adolescents with HIV
Raltegravir (Isentress) plus Atazanavir (Reyataz) Maintenance Therapy Appears Safe and Effective in Small Study
Short-term Enfuvirtide (Fuzeon) May Promote Long-term CD4 Cell Recovery in Patients Who Start Treatment Late
People Who Decline Routine HIV Testing Are More Likely to Be Positive; Written Consent Requirement May Discourage Testing
Monoclonal Antibody PRO 140 Demonstrates Good Tolerability and Potent Activity against CCR5-tropic HIV
Variations in "SEVI" Semen Component May Help Explain Racial/ethnic Differences in HIV Infection Rates
Effective Antiretroviral Therapy Leads to Improved Lung Function in People with HIV
Early Studies Demonstrate Potent Activity and Safety of Experimental Integrase Inhibitor S/GSK1265744
Once Daily Raltegravir (Isentress) Shows Promise in Pilot Study
Nevirapine (Viramune) and Boosted Atazanavir (Reyataz) Produce Comparable Early Virological and Immunological Response
Nutritional Formula Reduces CD4 Cell Decline in HIV Positive People Not Yet Taking Antiretroviral Therapy
New Injectable Drug Peramivir Is as Effective as Oseltamivir (Tamiflu) for Seasonal Influenza
IL-7 Improves CD4 and CD8 T-Cell Recovery among HIV Patients on Suppressive Antiretroviral Therapy
GRACE Trial shows Women Respond as well as Men to Etravirine (Intelence), but Blacks May Have Poorer Outcomes than Whites
CCR5 Antagonist Vicriviroc Demonstrates Long-Term Safety and Efficacy at 96 Weeks
At 96 Weeks, Raltegravir (Isentress) Is as Effective as Efavirenz (Sustiva) in Suppressing HIV Viral Load and Improving Immune Function
Tobacco and Marijuana May Significantly Lower Atazanavir (Reyataz) Blood Levels
Antiretroviral Pregnancy Registry Indicates Use of Tenofovir (Viread) by Pregnant Women Does Not Raise Risk of Birth Defects

Hepatitis B or C Articles
High-dose Hepatitis B Vaccination May Protect HIV Positive People Who Do Not Respond to a Standard Dose
HCV Re-infection Is Common, Mainly Due to Injection Drug Use, among Canadian Prisoners Treated for Hepatitis C
HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients
Experimental Agent ATI-0810 Appears to Have Novel Mechanism of Action against Hepatitis C Virus

HIV-HCV or HIV-HBV Coinfection Articles
Population-based Surveillance of Acute Hepatitis B and C Infection among Men Who Have Sex with Men
HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients
HIV Positive People May Respond Poorly to Pegylated Interferon without Ribavirin for Acute Hepatitis C
Resistance to Hepatitis B Drugs is Common among HIV/HBV Coinfected Patients Receiving Lamivudine-containing ART without Tenofovir (Viread)
 

 

 

 



 Google Custom Search


































































































 
HIV and Hepatitis.com is published by HIV and Hepatitis Treatment Advocates, Inc.